ArticleHepatology (Baltimore, Md.)2014
Is the adiponectin-AMPK-mitochondrial axis involved in progression of nonalcoholic fatty liver disease?
Article in Hepatology (Baltimore, Md.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between grip strength and non-alcoholic fatty liver disease: A systematic review and meta-analysis.Frontiers in medicine · 2022Pooled it
- Canonical and Non-Canonical Regulators of Lipid Metabolism in the Liver and the "Liver-Other Organs" Axes.International journal of molecular sciences · 2026Review
- HOPE and AMPK activation reduce reperfusion injury and metabolic dysfunction in primate steatotic liver grafts.Scientific reports · 2025Article
- A Systematic Review of Metabolic Syndrome: Key Correlated Pathologies and Non-Invasive Diagnostic Approaches.Journal of clinical medicine · 2024Review
- The Anti-Obesity and Anti-Steatotic Effects of Chrysin in a Rat Model of Obesity Mediated through Modulating the Hepatic AMPK/mTOR/lipogenesis Pathways.Molecules (Basel, Switzerland) · 2023Article
- Interaction between sarcopenia and nonalcoholic fatty liver disease.Clinical and molecular hepatology · 2023Review
- Synergistic activation of AMPK by AdipoR1/2 agonist and inhibitor of EDPs-EBP interaction recover NAFLD through enhancing mitochondrial function in mice.Acta pharmaceutica Sinica. B · 2023Article
- Dulaglutide Ameliorates Palmitic Acid-Induced Hepatic Steatosis by Activating FAM3A Signaling Pathway.Endocrinology and metabolism (Seoul, Korea) · 2022Article
- An Overview of the Molecular Mechanisms Contributing to Musculoskeletal Disorders in Chronic Liver Disease: Osteoporosis, Sarcopenia, and Osteoporotic Sarcopenia.International journal of molecular sciences · 2021Review
- Sarcopenia in chronic liver disease: mechanisms and countermeasures.American journal of physiology. Gastrointestinal and liver physiology · 2021Review
- AdipoR1/AdipoR2 dual agonist recovers nonalcoholic steatohepatitis and related fibrosis via endoplasmic reticulum-mitochondria axis.Nature communications · 2020Article
- The Role of Promyelocytic Leukemia Protein in Steatosis-Associated Hepatic Tumors Related to Chronic Hepatitis B virus Infection.Translational oncology · 2018Article
- Treatment of Diabetic Mice with a Combination of Ketogenic Diet and Aerobic Exercise via Modulations of PPARs Gene Programs.PPAR research · 2018Article
- IMM-H007, a new therapeutic candidate for nonalcoholic fatty liver disease, improves hepatic steatosis in hamsters fed a high-fat diet.FEBS open bio · 2017Article
- The Common Mechanisms of Sarcopenia and NAFLD.BioMed research international · 2017Review
- Diet-Induced Nonalcoholic Fatty Liver Disease Is Associated with Sarcopenia and Decreased Serum Insulin-Like Growth Factor-1.Digestive diseases and sciences · 2016Article
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.